Himanshu Sharma

Jan 30, 2025 | medium.com | Himanshu Sharma

Himanshu Sharma·Follow2 min read·--MY JOURNEY WITH THOSE HOSTEL FRIENDSGood morning everyoneAs every engineering aspirant who loves to prepare for entrance exams like jee, bits etc. I am one of them….. Yes i know every year lakhs of student gives the exam but only few of them get selected……so like every unselected student…..

Jan 10, 2025 | wfmz.com | Himanshu Sharma

REGIONAL LIVE CAMERAS: Bethlehem: Hotel Bethlehem | Main Street Reading: Penn Street Easton: Downtown Poconos: Jim Thorpe | Stroudsburg Bulletin: ...WIND ADVISORY REMAINS IN EFFECT UNTIL 1 AM EST FRIDAY... * WHAT...Northwest winds 15 to 25 mph with gusts up to 45 mph. * WHERE...Carbon and Monroe Counties. * WHEN...Until 1 AM EST Friday. * IMPACTS...Gusty winds will blow around unsecured objects. Treelimbs could be blown down and a few power outages may result.

Jan 10, 2025 | djournal.com | Himanshu Sharma

Personalised advertising and content, advertising and content measurement, audience research and services developmentStore and/or access information on a deviceYou can choose how your personal data is used.

Jan 10, 2025 | maqnews.com | Himanshu Sharma

...A Period of Light Snow for the Early Morning Commute... A period of light snow is expected to move across the area through7 AM. A dusting to a few tenths of an inch of accumulation ispossible. In addition, some patchy very light freezing drizzlecould mix in with the light snow. This may lead to roads becomingslick for the morning commute. If traveling early this morning,be alert for slick road conditions, especially on bridges,overpasses and secondary or lesser traveled roadways.

Jun 7, 2024 | nature.com | Katherine E. Kabotyanski |Ricardo Najera |Garrett P. Banks |Himanshu Sharma |Nicole R Provenza |Benjamin Y. Hayden | +2 more

Treatment-resistant depression (TRD) affects approximately 2.8 million people in the U.S. with estimated annual healthcare costs of $43.8 billion. Deep brain stimulation (DBS) is currently an investigational intervention for TRD. We used a decision-analytic model to compare cost-effectiveness of DBS to treatment-as-usual (TAU) for TRD. Because this therapy is not FDA approved or in common use, our goal was to establish an effectiveness threshold that trials would need to demonstrate for this therapy to be cost-effective. Remission and complication rates were determined from review of relevant studies. We used published utility scores to reflect quality of life after treatment. Medicare reimbursement rates and health economics data were used to approximate costs. We performed Monte Carlo (MC) simulations and probabilistic sensitivity analyses to estimate incremental cost-effectiveness ratios (ICER; USD/quality-adjusted life year [QALY]) at a 5-year time horizon. Cost-effectiveness was defined using willingness-to-pay (WTP) thresholds of $100,000/QALY and $50,000/QALY for moderate and definitive cost-effectiveness, respectively. We included 274 patients across 16 studies from 2009–2021 who underwent DBS for TRD and had ≥12 months follow-up in our model inputs. From a healthcare sector perspective, DBS using non-rechargeable devices (DBS-pc) would require 55% and 85% remission, while DBS using rechargeable devices (DBS-rc) would require 11% and 19% remission for moderate and definitive cost-effectiveness, respectively. From a societal perspective, DBS-pc would require 35% and 46% remission, while DBS-rc would require 8% and 10% remission for moderate and definitive cost-effectiveness, respectively. DBS-pc will unlikely be cost-effective at any time horizon without transformative improvements in battery longevity. If remission rates ≥8–19% are achieved, DBS-rc will likely be more cost-effective than TAU for TRD, with further increasing cost-effectiveness beyond 5 years.